Skip to content

US · DYAI · BIOTECHNOLOGY

Dyadic International, Inc. (DYAI) intrinsic value and stock valuation

$0.29as of 2026-11-21 · Mkt cap 35.33M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Dyadic International, Inc. DCF and intrinsic value

InvestorsCraft values DYAI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DYAI’s statements →

Dyadic International, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Jupiter, FL 33477-5094 dyadic.com

How the business is doing

Fiscal 2006–2025, USD

Revenue
$1.23M-5.1% 5y CAGRd
20062025
Net income
-$-7.36M
20062025
Free cash flow
-$-5.7M
20062025
Total equity
$1.23M-46.6% 5y CAGRd
20062025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2006–2025, USD
20252024202320222021
Revenue$1.23M$3.5M$2.9M$2.93M$2.4M
Operating income-$-7.15M-$-5.9M-$-8.23M-$-10.17M-$-14.73M
Net income-$-7.36M-$-5.81M-$-6.8M-$-9.74M-$-13.07M
EPSd-$-225.63K-$-198.16K-$-236.11K-$-343.44K-$-469.47K
Operating cash flow-$-5.7M-$-3.97M-$-6.73M-$-8.08M-$-11.28M
Capital expenditure$0.00-$0.00$0.00$0.00$0.00
Free cash flow-$-5.7M-$-3.97M-$-6.73M-$-8.08M-$-11.28M
Total assets$9.95M$9.93M$8.22M$13.7M$21.3M
Total debt$5.06M$5.07M$140K$0.00$0.00
Net debt$440K-$-1.44M-$-6.38M-$-5.79M-$-15.75M
Total equity$1.23M$2.47M$5.88M$11.1M$18.4M
Cash and short-term investments$7.32M$9.26M$7.26M$12.6M$20.3M
Income statement
20252024202320222021
Revenue$1.23M$3.5M$2.9M$2.93M$2.4M
Cost of revenue$2.32M$1.19M$1.98M$2.12M$1.94M
Gross profit-$-1.09M$2.3M$920K$810K$460K
Research and development expenses$2.15M$2.04M$3.3M$4.5M$8.39M
Selling, general and administrative expenses$5.76M$6.13M$5.82M$6.42M$6.7M
Other expenses-$-1.86M$20K$40K$50K$100K
Operating expenses$6.06M$8.2M$9.15M$11M$15.2M
Cost and expenses$8.38M$9.4M$11.1M$13.1M$17.1M
Interest income$280K$460K$420K$180K$50K
Interest expense$460K$430K$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$40K$0.00$3.49M
Ebitda-$-6.91M-$-5.38M-$-8.15M-$-10.12M-$-11.14M
Operating income-$-7.15M-$-5.9M-$-8.23M-$-10.17M-$-14.73M
Total other income/expenses, net-$-220K$90K$1.43M$430K$1.66M
Income before tax-$-7.36M-$-5.81M-$-6.8M-$-9.74M-$-13.07M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-7.36M-$-5.81M-$-6.8M-$-9.74M-$-13.07M
Weighted average shares outstanding$32.6M$29.3M$28.8M$28.4M$27.8M
Weighted average diluted shares outstanding$32.6M$29.3M$28.8M$28.4M$27.8M
Balance sheet
20252024202320222021
Cash and short-term investments$7.32M$9.26M$7.26M$12.6M$20.3M
Net receivables$1.13M$240K$470K$330K$370K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$9.9M$9.83M$8.07M$13.4M$21M
Property, plant and equipment, net$40K$90K$140K$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$280K$280K
Total non-current assets$50K$100K$150K$290K$290K
Total assets$9.95M$9.93M$8.22M$13.7M$21.3M
Accounts payable$850K$480K$660K$1.28M$1.55M
Short-term debt$30K$50K$50K$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$150K
Total current liabilities$3.69M$2.45M$2.25M$2.45M$2.56M
Long-term debt$5.03M$5.01M$90K$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$350K
Total non-current liabilities$5.03M$5.01M$90K$180K$350K
Capital lease obligations$30K$90K$140K$0.00$0.00
Total liabilities$8.71M$7.46M$2.34M$2.63M$2.91M
Common stock$50K$40K$40K$40K$40K
Retained earnings-$-93.45M-$-86.09M-$-80.28M-$-73.48M-$-63.75M
Accumulated other comprehensive income (loss)-$0.00-$0.00-$0.00-$0.00$0.00
Total equity$1.23M$2.47M$5.88M$11.1M$18.4M
Total investments$2.7M$2.76M$750K$7.13M$4.8M
Total debt$5.06M$5.07M$140K$0.00$0.00
Net debt$440K-$-1.44M-$-6.38M-$-5.79M-$-15.75M
Cash flow statement
20252024202320222021
Net income-$-7.36M-$-5.81M-$-6.8M-$-9.74M-$-13.07M
Depreciation and amortization-$-20K$0.00$0.00$0.00$0.00
Stock-based compensation$930K$1.13M$1.24M$1.89M$1.78M
Change in working capital$660K$750K-$-140K-$-320K$1.19M
Accounts receivable-$-860K$210K-$-90K-$-50K-$-10K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$310K-$-180K-$-650K-$-250K$550K
Net cash provided by operating activities-$-5.7M-$-3.97M-$-6.73M-$-8.08M-$-11.28M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$80K-$-1.88M$7.45M-$-2.37M$5.22M
Common stock issued$4.96M$20K$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.96M$5.85M$0.00$540K$1.23M
Net change in cash-$-650K-$-10K$720K-$-9.95M-$-4.89M
Cash at end of period$5.85M$6.51M$6.52M$5.79M$15.8M
Operating cash flow-$-5.7M-$-3.97M-$-6.73M-$-8.08M-$-11.28M
Capital expenditure$0.00-$0.00$0.00$0.00$0.00
Free cash flow-$-5.7M-$-3.97M-$-6.73M-$-8.08M-$-11.28M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Dyadic International, Inc.

        Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.

        CEO
        Mark A. Emalfarb
        Employees
        5
        Beta
        1.15

        Explore

        Frequently asked questions

        What is the intrinsic value of Dyadic International, Inc. (DYAI)?

        InvestorsCraft does not currently publish an intrinsic value for DYAI. How the IC value is calculated.

        Is DYAI undervalued?

        InvestorsCraft does not publish an undervaluation signal for DYAI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.